Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin’s lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751)

Bowen Wang, Luming Cao, Jia Li, Yangzhi Zhao, Junna Li, Yueyue Wen, Panpan Yan, Wei Guo, Ou Bai · 2025

Read Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin’s lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751) by Bowen Wang, Luming Cao, Jia Li, Yangzhi Zhao, Junna Li, Yueyue Wen, Panpan Yan, Wei Guo, Ou Bai (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12776184.txt.

Description

Bowen Wang and co-authors report a 2025 randomized trial of a long acting drug that prevents low white cell counts during chemotherapy. Low counts are a common and risky side effect for lymphoma patients. The long acting form, PEG-rhG-CSF, was compared with the standard daily form.

The trial enrolled 154 patients at one hospital in China between 2020 and 2022, split evenly between the two drugs. In the first treatment cycle, severe low counts lasted about a day and a half on the long acting drug versus more than two days on the standard form. Rates of severe low counts and fever cases were also compared. Subgroup checks by regimen and tumor origin were included in the analysis.

Catalog record

CREATORBowen Wang, Luming Cao, Jia Li, Yangzhi Zhao, Junna Li, Yueyue Wen, Panpan Yan, Wei Guo, Ou Bai
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12776184

Browse the full library · About the Tower of Babel